Literature DB >> 22213084

Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model.

Anna K Clark1, John Grist, Adam Al-Kashi, Mauro Perretti, Marzia Malcangio.   

Abstract

OBJECTIVE: The induction of rheumatoid arthritis (RA) by active and passive immunization of mice results in the development of pain at the same time as the swelling and inflammation, with both peripheral and central sensitization contributing to joint pain. The purpose of this study was to examine the development of pain in the rat model of collagen-induced arthritis (CIA) and to evaluate the contribution of neuroimmune interactions to established arthritis pain.
METHODS: Mechanical hypersensitivity was assessed in female Lewis rats before and up to 18 days after induction of CIA by immunization with type II collagen. The effect of selective inhibitors of microglia were then evaluated by prolonged intrathecal delivery of a cathepsin S (CatS) inhibitor and a fractalkine (FKN) neutralizing antibody, from day 11 to day 18 following immunization.
RESULTS: Rats with CIA developed significant mechanical hypersensitivity, which started on day 9, before the onset of clinical signs of arthritis. Mechanical hypersensitivity peaked with the severity of the disease, when significant microglial and astrocytic responses, alongside T cell infiltration, were observed in the spinal cord. Intrathecal delivery of microglial inhibitors, a CatS inhibitor, or an FKN neutralizing antibody attenuated mechanical hypersensitivity and spinal microglial response in rats with CIA.
CONCLUSION: The inhibition of microglial targets by centrally penetrant CatS inhibitors and CX(3) CR1 receptor antagonists represents a potential therapeutic avenue for the treatment of pain in RA.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22213084     DOI: 10.1002/art.34351

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

Review 1.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

2.  Cysteine Cathepsins Activate ELR Chemokines and Inactivate Non-ELR Chemokines.

Authors:  Urska Repnik; Amanda E Starr; Christopher M Overall; Boris Turk
Journal:  J Biol Chem       Date:  2015-04-01       Impact factor: 5.157

3.  Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis.

Authors:  R E Miller; P B Tran; S Ishihara; D Syx; D Ren; R J Miller; A M Valdes; A M Malfait
Journal:  Osteoarthritis Cartilage       Date:  2020-01-23       Impact factor: 6.576

4.  Selective activation of microglia facilitates synaptic strength.

Authors:  Anna K Clark; Doris Gruber-Schoffnegger; Ruth Drdla-Schutting; Katharina J Gerhold; Marzia Malcangio; Jürgen Sandkühler
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

Review 5.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

Review 6.  Mechanisms, impact and management of pain in rheumatoid arthritis.

Authors:  David A Walsh; Daniel F McWilliams
Journal:  Nat Rev Rheumatol       Date:  2014-05-27       Impact factor: 20.543

7.  Monocytes/Macrophages control resolution of transient inflammatory pain.

Authors:  Hanneke L D M Willemen; Niels Eijkelkamp; Anibal Garza Carbajal; Huijing Wang; Matthias Mack; Jitske Zijlstra; Cobi J Heijnen; Annemieke Kavelaars
Journal:  J Pain       Date:  2014-05       Impact factor: 5.820

8.  The analgesic effect and possible mechanisms by which koumine alters type II collagen-induced arthritis in rats.

Authors:  Gui-Lin Jin; Jian Yang; Wan-Qing Chen; Jie Wang; Hong-Qiang Qiu; Ying Xu; Chang-Xi Yu
Journal:  J Nat Med       Date:  2018-07-27       Impact factor: 2.343

Review 9.  TRPV4 as a therapeutic target for joint diseases.

Authors:  Amy L McNulty; Holly A Leddy; Wolfgang Liedtke; Farshid Guilak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-18       Impact factor: 3.000

10.  Granulocyte-colony-stimulating factor (G-CSF) signaling in spinal microglia drives visceral sensitization following colitis.

Authors:  Lilian Basso; Tamia K Lapointe; Mircea Iftinca; Candace Marsters; Morley D Hollenberg; Deborah M Kurrasch; Christophe Altier
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.